RBN012759, a newly developed selective PARP14 inhibitor focused on PARP14’s role in immunotherapy, has shown a reversion of IL-4-directed pro-tumor genes, indicating the potential to employ the inhibitor as an anticancer therapeutic. The gene discussed is PARP14; the disease is neoplasm.